Markets

Insider Trading

Hedge Funds

Retirement

Opinion

1281292 - 11759070 - 1

10 Best Healthcare Stocks to Buy with Highest Upside Potential

Page 1 of 4

In this article, we will look at the 10 Best Healthcare Stocks to Buy with the Highest Upside Potential.

On June 1, Tom Lee, Fundstrat managing partner and head of research, and Fundstrat Capital CIO, appeared on CNBC’s ‘Squawk Box’ to talk about the latest market trends, the market outlook, and more.

He believes that although 2026 was expected to be a tough year, and is as well, there are several tailwinds, including the AI story. However, Lee was of the view that we still might face challenges between now and December, and so everyone still needs to be vigilant. Generally, he is bullish and expects market breadth to improve in June.

READ ALSO: 10 Best Stocks to Buy Now for Long Term Growth AND Top 10 Undervalued Blue Chip Stocks Analysts Recommend for Smart Investing

Talking about the future, he thinks a couple of things are coming together, a few of which may only happen once in a lifetime. One of them is that the US economic growth rate is starting to step up, which, in other words, means that we could grow at 4%. For the world’s largest economy to start accelerating growth is “pretty astounding” to him. Lee still sees a 3-phase market in 2026 and believes that it may rise closer to 7,700. There is the possibility that the decline due to headwinds may pressure stocks in a way that feels like a bear market. Post-Midterms, he thinks we can rally strongly.

With these broader market trends in view, let’s look at the best healthcare stocks to buy with the highest upside potential.

Our Methodology

We used the Finviz stock screener to identify the best healthcare stocks that analysts are bullish on and selected the top 10 stocks most popular among hedge funds as of Q1 2026, using the hedge fund sentiment data from Insider Monkey’s database. The stocks are arranged in ascending order of analyst upside.

Note: All data was recorded on June 2.

Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Insider Monkey’s quarterly newsletter strategy selects 14 small-cap and large-cap stocks every quarter and has returned 599.2% since May 2014, beating its benchmark by 372 percentage points (see more details here).

10 Best Healthcare Stocks to Buy with Highest Upside Potential

10. Abbott Laboratories (NYSE:ABT)

Analyst Upside: 31.01%

Abbott Laboratories (NYSE:ABT) is one of the best healthcare stocks to buy with highest upside potential. Abbott Laboratories (NYSE:ABT) announced on May 27 that it has secured CE Mark for the world’s first dual glucose‑ketone sensing technology for people with diabetes. The systems are branded as Libre Duo and Libre Duo 10 Day, and are specifically designed to make continuous measurements of glucose and ketone levels every minute. They provide real-time visibility into both glucose levels and rising ketones, which is necessary for daily diabetes management. Management stated that the technology marks the first time people with diabetes will be able to monitor ketones without traditional blood or urine tests, as rising ketones can lead to a diabetic ketoacidosis (DKA) emergency. Abbott Laboratories (NYSE:ABT) has plans to begin the launch of Libre Duo systems in select European countries later this year.

In a separate development, Abbott Laboratories (NYSE:ABT) announced on May 27 that the American Cancer Society (ACS) released updated colorectal cancer (CRC) screening guidelines that reaffirm Cologuard® and Cologuard Plus® as preferred noninvasive screening options for adults aged 45 and older who are at average risk for CRC.

Abbott Laboratories (NYSE:ABT) discovers, develops, manufactures, and sells healthcare products. The company’s operations are divided into the following segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices.

9. Danaher Corporation (NYSE:DHR)

Analyst Upside: 36.21%

Danaher Corporation (NYSE:DHR) is one of the best healthcare stocks to buy with highest upside potential. Wolfe Research downgraded Danaher Corporation (NYSE:DHR) to Peer Perform from Outperform on June 1 without assigning a price target after assuming coverage of the name. It stated that growth forward and backward is similar, and Thermo Fisher is “a little cheaper on P/E”. It added that the Masimo (MASI) transaction “confused us about DHR’s identity.”

Danaher Corporation (NYSE:DHR) also received a rating update from RBC Capital on May 14. The firm resumed coverage of the stock with an Outperform rating, setting a price target of $200. The firm told investors in a research note that it sees the company’s growth recovering with an improvement in the bioprocess market. It further added that factors like the lapping of “idiosyncratic headwinds”, a sustained bioprocess rebound, and end market improvement put the company’s 6% revenue growth target within reach for 2027.

Danaher Corporation (NYSE:DHR) designs, manufactures, and markets professional, medical, industrial, and commercial products and services, making it a significant diagnostics stock. It operates through Diagnostics, Biotechnology, Life Sciences, and Environmental and Applied Solutions.

Page 1 of 4

The $250 Trillion AI Hype is Real. A few years from now, you’ll probably wish you’d bought this stock.

Dr. Inan Dogan

Dr. Ian Dogan

Co-Founder and Research Director at Insider Monkey

When Jeff Bezos said that one breakthrough technology would shape Amazon’s destiny, even Wall Street’s biggest analysts were caught off guard.

Fast forward a year and Amazon’s new CEO Andy Jassy described generative AI as a “once-in-a-lifetime” technology that is already being used across Amazon to reinvent customer experiences.

At the 8th Future Investment Initiative conference, Elon Musk predicted that by 2040 there would be at least 10 billion humanoid robots, with each priced between $20,000 and $25,000.

Do the math. According to Musk, this technology could be worth $250 trillion by 2040.

Put another way, that’s roughly equal to:

  • 175 Teslas
  • 107 Amazons
  • 140 Metas
  • 84 Googles
  • 65 Microsofts
  • And 55 Nvidias

And here’s the wild part — this $250 trillion wave isn’t tied to one company, but to an entire ecosystem of AI innovators set to reshape the global economy.

It’s a leap so massive, it could reshape how businesses, governments, and consumers operate worldwide.

Even if that $250 trillion figure sounds ambitious, major firms like PwC and McKinsey still see AI unlocking multi-trillion-dollar potential.

How could anything be worth that much?

The answer lies in a breakthrough so powerful it’s redefining how humanity works, learns, and creates.

And this breakthrough has already set off a frenzy among hedge funds and Wall Street’s top investors.

What most investors don’t realize is that one under-owned company holds the key to this $250 trillion revolution.

In fact, Verge argues this company’s supercheap AI technology should concern rivals.

Before I reveal the details, let’s talk about how some of the richest people on the planet are positioning themselves.

  • Bill Gates sees artificial intelligence as the “biggest technological advance in my lifetime,” more transformative than the internet or personal computer, capable of improving healthcare, education, and addressing climate change.
  • Larry Ellison — through Oracle, is spending billions on Nvidia chips and partnering with Cohere to embed generative AI across Oracle’s cloud and apps.
  • Warren Buffett — not known for tech hype — says this breakthrough could have a ‘hugely beneficial social impact.

When billionaires from Silicon Valley to Wall Street line up behind the same idea — you know it’s worth paying attention to.

Even as we admire what Tesla, Nvidia, Alphabet, and Microsoft have built, we believe an even greater opportunity lies elsewhere…

But the real story isn’t Nvidia — it’s a much smaller company quietly improving the critical technology that makes this entire revolution possible.

And judging by what I’m hearing from both Silicon Valley insiders and Wall Street veterans…

This prediction might not be bold at all:

A few years from now, you’ll wish you’d owned this stock.

The best part? You can discover everything about this company and its groundbreaking technology right now.

I’ve compiled everything you need to know about this groundbreaking company in a detailed, members-only report.

Trust me — you’ll want to read this report before putting another dollar into any tech stock.

For a ridiculously low price of just $9.99 a month, you can unlock a year’s worth of in-depth investment research and exclusive insights – that’s less than a single fast food meal!

Here’s what to do next:

1. Subscribe to our Premium Readership Newsletter for just $9.99 a month. (33% Off – was $14.99).

2. Enjoy a year of ad-free browsing, exclusive access to our in-depth report on the revolutionary AI company, and the upcoming issues of our Premium Readership Newsletter over the next 12 months.

3. Sit back, relax, and know that you’re backed by our ironclad 30-day money-back guarantee.

Don’t miss out on this incredible opportunity! Subscribe now and take control of your AI investment future!

No worries about auto-renewals! Our 30-Day Money-Back Guarantee applies whether you’re joining us for the first time or renewing your subscription a month later!

 

Wall Street calls this $3 stock a “Melting Ice Cube.” They said the same thing about BTI before it returned 90%.

Dr. Inan Dogan

Dr. Ian Dogan

Co-Founder and Research Director at Insider Monkey

My name is Inan Dogan. I’m the co-founder and Research Director of Insider Monkey. I have an important message for you today.

Since March 2017, my stock picks have returned 16.5% annually. Today, I’ve found an opportunity even bigger than my British American Tobacco call.

Two years ago, Wall Street wrote off British American Tobacco (BTI) as a “melting ice cube.” The stock had crashed 40% from its peak, and consensus said the business was dying.

We looked under the cover and realized they were wrong.

We alerted our subscribers, and BTI returned 90% in just 16 months.

Now if you had invested just $10,000 in BTI in June 2024, you’d be sitting on $19,000 in October 2025.

Today, we have identified a nearly identical pattern in a digital-first giant trading at $3.

While the market panics over a surface-level revenue decline, our PhD-led research shows management has actually surgically cut $100 million in waste to focus on high-margin growth.

This pattern is a hallmark of our 16.5% annual return track record. The current opportunity offers a 400% upside potential—dwarfing even our 90% BTI return.

Get the ticker for our new “Underdog” pick and the full BTI case study for just 99 cents.

This exclusive offer is for NEW newsletter subscribers ONLY! Join our Premium Readership Newsletter for only $0.99 and become part of a savvy investor community.!

This offer vanishes in 7 days, so don’t miss your chance to lock in market beating returnsSign up NOW! The monthly newsletter comes with a 30-day, no-risk money-back guarantee. This offer is available to the first 1000 new investors who respond.

Regular price $9.99/mo. Cancel anytime.

Space is Limited! Only 1000 spots are available for this exclusive offer. Don’t let this chance slip away – subscribe to our Premium Readership Newsletter today and unlock the potential for a life-changing investment.

Here’s what to do next:

1. Head over to our website and subscribe to our Premium Readership Newsletter for just $0.99.

2. Enjoy a month of ad-free browsing, exclusive access to our in-depth report on the Trump tariff and nuclear energy company as well as the revolutionary AI-robotics company, and the upcoming issues of our Premium Readership Newsletter.

3. Sit back, relax, and know that you’re backed by our ironclad 30-day money-back guarantee.

Don’t miss out on this incredible opportunity! Subscribe now and take control of your AI investment future!

Regular price $9.99/mo. Cancel anytime.